Publication | Closed Access

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study

MedicineCancer ManagementPharmacologyPathologyAdvanced Solid TumorsTumor TargetingAnti-cancer AgentCancer TreatmentOncologyRadiation OncologyCancer Research